Stock Price, News, Quote and Profile of ABCELLERA BIOLOGICS INC(NASDAQ:ABCL) stock

ABCELLERA BIOLOGICS INC

NASDAQ:ABCL (1/3/2025, 8:17:58 PM)

After market: 3.15 +0.02 (+0.64%)

3.13

+0.1 (+3.3%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryLife Sciences Tools & Services

GICS SubIndustryLife Sciences Tools & Services

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%-70%

Sales Q2Q%-1.39%

CRS20.62

6 Month16.36%

Overview

Earnings (Last)11-04 2024-11-04/amc

Earnings (Next)02-18 2025-02-18/amc

Ins Owners9.04%

Inst Owners37.11%

Market Cap924.51M

Shares295.37M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts82.67

Short Float %7.61%

Short Ratio6.22

IPO12-11 2020-12-11

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 586 full-time employees. The company went IPO on 2020-12-11. The Company’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the antibody discovery problems. The firm has developed technology platforms to unlock drug classes, targets, and modalities, including transmembrane proteins, T-cell engagers, and peptide-MHCs. The firm is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two preclinical programs in its internal pipeline are ABCL575 and ABCL635. ABCL635 is an antibody-drug candidate against an undisclosed target with an indication in metabolic and endocrine conditions. ABCL575 targets OX40 ligand and is being developed as a therapy for the treatment of atopic dermatitis and other indications of autoimmunity and inflammation.